整合代谢组学揭示门静脉血清代谢组改变参与肝细胞癌发生
该研究对52例肝细胞癌(HCC)患者和50例健康对照的发现队列及50例HCC和50例健康对照的验证队列,进行血清(门静脉和中心静脉)、肝组织和粪便的整合代谢组学分析。HCC患者门静脉血清和癌组织中DL-3-苯乳酸、L-色氨酸、甘胆酸和1-甲基烟酰胺水平升高,与肝功能受损和生存不良相关;而亚油酸和苯酚水平降低,且体外实验显示二者抑制HCC增殖。
要点
- HCC患者门静脉血清和癌组织中DL-3-苯乳酸、L-色氨酸、甘胆酸和1-甲基烟酰胺升高。
- 上述代谢物升高与肝功能受损和生存不良相关。
- 门静脉和粪便中亚油酸和苯酚降低,体外显示二者抑制HCC增殖。
核心结论
- 血清、组织和粪便整合代谢组学分析揭示了HCC患者未报道的代谢改变。
- 门静脉中升高和降低的代谢物可能参与HCC发生发展。
研究设计与样本
- 发现队列纳入102名受试者(52例HCC患者和50例健康对照)。
- 独立验证队列纳入100名受试者(50例HCC患者和50例健康对照)。
- 采集血清(门静脉和中心静脉)、肝组织(HCC肿瘤及癌旁非肿瘤、正常肝)和粪便样本。
- 采用高效液相色谱-质谱进行非靶向代谢组学分析,并在肝细胞系中验证候选代谢物功能。
主要发现
- HCC患者与对照个体的血清、肝组织和粪便代谢物聚类明显不同(p<0.001)。
- HCC患者门静脉血清和HCC组织中DL-3-苯乳酸、L-色氨酸、甘胆酸和1-甲基烟酰胺水平显著高于健康对照。
- 上述代谢物水平与肝功能受损和生存不良相关。
- HCC患者门静脉和粪便中亚油酸和苯酚水平低于健康对照。
- 亚油酸和苯酚显著抑制HCC增殖,提示其作为保护性代谢物的抗HCC功能。
临床怎么用
- 门静脉血清代谢物谱可能有助于识别HCC相关代谢改变。
- DL-3-苯乳酸、L-色氨酸、甘胆酸和1-甲基烟酰胺等升高代谢物与肝功能受损和生存不良相关,或可作为预后参考。
- 亚油酸和苯酚在体外抑制HCC增殖,提示其潜在保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Altered metabolites are important for the tumourigenicity of hepatocellular carcinoma (HCC). We performed integrative metabolomics analysis of the metabolites changes in portal venous blood and in comparison with the metabolites changes in liver tissues and stool samples of HCC patients and healthy liver donors. DESIGN: Serum (portal and central vein), liver tissue (HCC tumour and adjacent non-tumour, normal liver) and stool samples were collected from 102 subjects (52 HCC patients and 50 healthy controls) in the discovery cohort; and 100 subjects (50 HCC patients and 50 healthy controls) in an independent validation cohort. Untargeted metabolomic profiling was performed using high-performance liquid chromatography-mass spectrometry. The function of candidate metabolites was validated in hepatocyte cell lines. RESULTS: Detailed metabolomic evaluation showed distinct clusters of metabolites in serum, liver tissue and stool samples from patients with HCC and control individuals (p<0.001). HCC patients had significantly higher levels of portal vein serum and HCC tissue metabolites of DL-3-phenyllactic acid, L-tryptophan, glycocholic acid and 1-methylnicotinamide than healthy controls, which were associated with impaired liver function and poor survival. On the other hand, HCC patients had lower levels of linoleic acid and phenol in portal vein and stool samples than healthy controls. Linoleic acid and phenol significantly inhibited HCC proliferation, inferring their anti-HCC function as protective metabolites. CONCLUSIONS: The integrative metabolome analysis of serum, tissue and stool metabolites revealed unreported metabolic alterations in HCC patients. In portal vein, we identified elevated and depleted metabolites signifying that they might play a role in HCC development.
引用
- Liu J, Geng W, Sun H, et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. Gut. 2021. PMID: 34344785. doi:10.1136/gutjnl-2021-325189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。